Pharmaceuticals News and Research

RSS

SLU biostatistician encourages people to interpret scientific and medical research

Thanks to the internet, access to research studies, medical news and health websites is greater than ever, offering instant admission to the world of medical knowledge.

29 Sep 2015

UT Southwestern Medical Center geneticist named 2015 recipient of Pearl Meister Greengard Prize

UT Southwestern Medical Center geneticist Dr. Helen Hobbs is the 2015 recipient of the prestigious Pearl Meister Greengard Prize. The prize recognizes Dr. Hobbs' research, which advances understanding of heart disease and other complex disorders.

29 Sep 2015

Philip Chapper & Co to showcase new partner products at Europe’s largest pharmaceutical trade fair

Philip Chapper & Company Ltd, a UK company with over 40 years’ experience within medical supplies, is to showcase innovative products from new suppliers at the industry’s largest European trade fair.

28 Sep 2015

Novel device to mass produce Lidocaine

One of the world’s most in-demand anaesthetics can now be produced on the spot, thanks to the thermos-flask sized device that recently won Flinders University inventor Professor Colin Raston an Ig Nobel prize.

28 Sep 2015

Teva presents new Reslizumab data at European Respiratory Society (ERS) International Congress 2015

Teva Pharmaceutical Industries Ltd., has presented results from a post hoc analysis of two pivotal Phase III clinical trials showing that treatment with reslizumab reduced clinical asthma exacerbations (CAEs) by 75 percent versus placebo in a subgroup of patients with late onset asthma (diagnosed at 40 years of age and older) with elevated blood eosinophils, who were inadequately controlled on inhaled corticosteroids (ICS).

28 Sep 2015

ILUVIEN continues to show positive results in Europe

Alimera Sciences Limited, the European subsidiary of Alimera Sciences, Inc., a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, announced the availability of real world data from 28 injections of ILUVIEN (Fluocinolone Acetonide 190 micrograms intravitreal implant in applicator) in Europe, presented in a review paper authored by Fahd Quhill, Consultant Ophthalmologist, Department of Ophthalmology, Royal Hallamshire Hospital, Sheffield, South Yorkshire, U.K.

28 Sep 2015

FDA accepts Braeburn's resubmission of Probuphine NDA for review

Braeburn Pharmaceuticals, an Apple Tree Partners company, today announced that the U.S. Food and Drug Administration has accepted Braeburn's resubmission of the Probuphine New Drug Application (NDA) for review and set February 27, 2016 as the target date for Agency action.

28 Sep 2015

Kolltan announces presentation of data from KTN0158 preclinical study in mast cell tumors at ESMO 2015

Kolltan Pharmaceuticals, Inc. today announced the presentation of data from a preclinical study evaluating KTN0158 in dogs with spontaneous mast cell tumors. KTN0158 is a proprietary, humanized anti-KIT IgG1 monoclonal antibody drug candidate being developed as a potential therapy for cancer and mast cell-related diseases.

28 Sep 2015

Researchers develop methodology to monitor changes in DNA methylation patterns in individual cells

Whitehead Institute researchers have developed a methodology to monitor changes in DNA methylation over time in individual cells.

26 Sep 2015

Genovate begins construction of Insulin Ecological Industrial Park in Changzhou National Hi-tech District

On September 22, construction of phase I of Genovate Biotechnology's Insulin Ecological Industrial Park began in Changzhou National Hi-tech District. Changzhou mayor Fei Gaoyun said the city and district governments and the relevant oversight authorities will do their best to provide support services, with the aim of doing what is needed to see construction completed and the facility put into production as early as possible.

26 Sep 2015

Apax-advised funds sign definitive agreement to acquire interest in Ideal Protein

Funds advised by Apax Partners LLP, a global private equity firm, today announced that they have entered into a definitive agreement to acquire an interest in Ideal Protein, a proprietary weight loss and wellness solutions company. Terms of the transaction were not disclosed.

26 Sep 2015

Allergan releases generic INVEGA (paliperidone extended-release tablets) in the U.S.

Allergan plc, a leading global pharmaceutical company, today announced that it has launched a generic version of Janssen's INVEGA (paliperidone extended-release tablets) in the U.S. Allergan is the first company to receive FDA approval for and launch a generic version of INVEGA, demonstrating the deep expertise of the Company's global generics R&D, regulatory and supply chain teams.

25 Sep 2015

AbbVie plans to advance ABT-494 to Phase 3 studies in rheumatoid arthritis

AbbVie, a global biopharmaceutical company, today announced that it will advance ABT-494, its internally developed investigational selective JAK1 inhibitor, to Phase 3 studies in rheumatoid arthritis. Following a thorough review of available data, AbbVie will not exercise its right to in-license the Galapagos JAK1 inhibitor, filgotinib.

25 Sep 2015

AbbVie reports positive results from ABT-494 Phase 2 clinical trials in patients with rheumatoid arthritis

AbbVie, a global biopharmaceutical company, today announced results from two Phase 2 clinical trials evaluating its investigational selective JAK1 inhibitor, ABT-494, in patients with inadequate response to either methotrexate or TNF inhibitors.

25 Sep 2015

NNFF's Lifetime Health-Science Achievement Award 2015 goes to John Crew and Ron Najafi

The National Necrotizing Fasciitis Foundation today announced that it has awarded NNFF's Lifetime Health-Science Achievement Award 2015 to John Crew, MD and Ron Najafi, PhD for "Excellence in Innovative Healthcare". Their pioneering work has improved care for patients with life-threatening 'flesh-eating' disease and other types of wounds.

25 Sep 2015

Camber Pharmaceuticals releases generic version of Nexium (Esomeprazole) capsules

Camber Pharmaceuticals is pleased to announce that it has launched Esomeprazole Magnesium Delayed-Release Capsules, 20 mg and 40 mg, which is the generic version of Nexium (Esomeprazole) capsules from AstraZeneca Pharmaceuticals. The product is indicated for the treatment of heartburn, gastroesophageal reflux disease (GERD), stomach ulcers, and for a damaged esophagus.

24 Sep 2015

Duke Raleigh Hospital becomes first healthcare facility to use certified mobile compounding cleanroom

Duke Raleigh Hospital recently became the first healthcare facility to utilize a certified USP 797 mobile cleanroom to assure uninterrupted pharmacy services. The advanced pharmacy unit, created by Germfree Labs, allowed the hospital to maintain separate, on-site sterile drug compounding operations during a major renovation project.

24 Sep 2015

Alimera Sciences announces results from ongoing study on ILUVIEN

Alimera Sciences, Inc., a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, announced that Alimera Sciences Limited, its European subsidiary based in London, revealed interim six-month data on ILUVIEN (Fluocinolone Acetonide 190 micrograms intravitreal implant in applicator) from the ongoing study referred to as RESPOND, a non-Randomised, open-label, multicenter phase 4 pilot study on the Effect and Safety of ILUVIEN Fluocinolone Acetonide in chronic diabetic macular edema Patients cOnsidered iNsufficiently responsive to available therapies with or without intravitreal corticosteroiD therapy.

24 Sep 2015

WPI awarded NIH grant to design new pharmaceuticals, simplify manufacturing of existing drugs

The National Institutes of Health has awarded $346,000 to Worcester Polytechnic Institute for a three-year research project to advance development of a chemical process that could significantly improve the ability to design new pharmaceuticals and streamline the manufacturing of existing drugs.

24 Sep 2015

Study raises questions about direct applicability of clinical trial data for cancer drugs

When prescribing newly approved drugs, physicians rely on data from clinical trials to understand the benefits and risks of those drugs for patients. But a study published in the Journal of Oncology Practice showed that for certain cancer drugs, participants in clinical trials are often not representative of the patients that ultimately take the drugs, raising questions about the direct applicability of trial data.

24 Sep 2015

Pharmaceuticals News and Research

SLU biostatistician encourages people to interpret scientific and medical research

UT Southwestern Medical Center geneticist named 2015 recipient of Pearl Meister Greengard Prize

Philip Chapper & Co to showcase new partner products at Europe’s largest pharmaceutical trade fair

Novel device to mass produce Lidocaine

Teva presents new Reslizumab data at European Respiratory Society (ERS) International Congress 2015

ILUVIEN continues to show positive results in Europe

FDA accepts Braeburn's resubmission of Probuphine NDA for review

Kolltan announces presentation of data from KTN0158 preclinical study in mast cell tumors at ESMO 2015

Researchers develop methodology to monitor changes in DNA methylation patterns in individual cells

Genovate begins construction of Insulin Ecological Industrial Park in Changzhou National Hi-tech District

Apax-advised funds sign definitive agreement to acquire interest in Ideal Protein

Allergan releases generic INVEGA (paliperidone extended-release tablets) in the U.S.

AbbVie plans to advance ABT-494 to Phase 3 studies in rheumatoid arthritis

AbbVie reports positive results from ABT-494 Phase 2 clinical trials in patients with rheumatoid arthritis

NNFF's Lifetime Health-Science Achievement Award 2015 goes to John Crew and Ron Najafi

Camber Pharmaceuticals releases generic version of Nexium (Esomeprazole) capsules

Duke Raleigh Hospital becomes first healthcare facility to use certified mobile compounding cleanroom

Alimera Sciences announces results from ongoing study on ILUVIEN

WPI awarded NIH grant to design new pharmaceuticals, simplify manufacturing of existing drugs

Study raises questions about direct applicability of clinical trial data for cancer drugs

A guide to density measurement excellence eBook

Latest eBooks

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Improving healthcare sustainability through carbon data

A New Approach to Preventing Bladder Cancer Recurrence

Bringing real-time analytics to downstream bioprocess monitoring